Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Blodglukosesenkende legemidler ved type 2-diabetes
Engelsk titel: Oral glucose lowering drugs against type 2 diabetes Läs online Författare: Aas, Vigdis ; Lund, Jenny ; Kase, Eili T ; Feng, Yuan Z ; Rustan, Arild C ; Thoresen, Hege Språk: Nor Antal referenser: 32 Dokumenttyp: Översikt UI-nummer: 15063976

Tidskrift

Norsk Farmaceutisk Tidsskrift 2015;123(5)20-4 ISSN 0029-1935 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

Background This review gives an overview of the available drugs, except insulin, for treatment of hyperglycemia in type 2 diabetes. The mechanisms of action, clinical effects, clinical use and the most common adverse effects are summarized. Material and methods The review is based on a qualified selection of relevant articles found by searching the PubMed database. Results and conclusion Treatment of hyperglycemia in type 2 diabetes can be challenging, and the achievement of blood glucose control often requests multifaceted approaches. Life style intervention is fundamental to all drug regimes, and the patients should be motivated for and educated in the importance of physical activity, a healthy diet and weight reduction if overweight. If this does not lead to desired blood glucose level, medical treatment should be initiated, and combinations of drugs with different targets are often required. Metformin is considered the first-line therapy for most patients. The blood glucose lowering efficacy for metformin, sulfonylureas and glitazones is about 1–1.5 % reduction in HbA1c, whereas DPP4 inhibitors, GLP-1 analogs, SGLT2 inhibitors and acarbose show a slightly lower effect. The choice of treatment will depend on individual characteristics and the degree of hyperglycemia.